Ann: Trading halt, page-317

i agree with the addition to the board, make sense,(a corporate update) as Novartis would want a say, and protect their interests,
I had posed the question whether there were milestones payments around yesterday results, even thought is was secondary endpoint- and/or MSB gets approval with 60% mortality rate, which was the real endpoint that the FDA advised they were interested in seeing on the way to approval?
would Novartis upgrade there agreement in such a short time? only reason i could see if, Novartis believe their own pipelines etc don't have the potential as MSB, or even in combined use? ,
it could as sort of cheap buyin from Novartis rather than a TO, with a injection in part.